$562 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 59 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDGL | New | MADRIGAL PHARMACEUTICALS INC | $9,734,000 | – | 34,803 | +100.0% | 1.73% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $7,931,000 | – | 60,000 | +100.0% | 1.41% | – |
| VKTX | New | VIKING THERAPEUTICS INC | $7,118,000 | – | 750,000 | +100.0% | 1.27% | – |
| REGN | New | REGENERON PHARMACEUTICALSput | $6,900,000 | – | 20,000 | +100.0% | 1.23% | – |
| OBSV | New | OBSEVA SA | $6,424,000 | – | 424,300 | +100.0% | 1.14% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $6,323,000 | – | 160,000 | +100.0% | 1.13% | – |
| ZGNX | New | ZOGENIX INC | $4,884,000 | – | 110,500 | +100.0% | 0.87% | – |
| CHRS | New | COHERUS BIOSCIENCES INC | $4,830,000 | – | 345,000 | +100.0% | 0.86% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $4,140,000 | – | 450,000 | +100.0% | 0.74% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $3,696,000 | – | 168,000 | +100.0% | 0.66% | – |
| ZGNX | New | ZOGENIX INCcall | $3,647,000 | – | 82,500 | +100.0% | 0.65% | – |
| MEIP | New | MEI PHARMA INC | $3,468,000 | – | 880,087 | +100.0% | 0.62% | – |
| New | INOTEK PHARMACEUTICALS CORPnote 5.750% 8/0 | $3,022,000 | – | 3,000,000 | +100.0% | 0.54% | – | |
| ARWR | New | ARROWHEAD PHARMACEUTICALS INcall | $2,720,000 | – | 200,000 | +100.0% | 0.48% | – |
| ZFGN | New | ZAFGEN INC | $2,558,000 | – | 250,000 | +100.0% | 0.46% | – |
| ACER | New | ACER THERAPEUTICS INC | $2,360,000 | – | 109,270 | +100.0% | 0.42% | – |
| MGTA | New | MAGENTA THERAPEUTICS INC | $2,295,000 | – | 170,000 | +100.0% | 0.41% | – |
| TSRO | New | TESARO INC | $2,224,000 | – | 50,000 | +100.0% | 0.40% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO Lcall | $2,126,000 | – | 53,800 | +100.0% | 0.38% | – |
| ZGNX | New | ZOGENIX INCput | $1,989,000 | – | 45,000 | +100.0% | 0.35% | – |
| VCEL | New | VERICEL CORP | $1,844,000 | – | 190,055 | +100.0% | 0.33% | – |
| EDIT | New | EDITAS MEDICINE INCcall | $1,792,000 | – | 50,000 | +100.0% | 0.32% | – |
| KZR | New | KEZAR LIFE SCIENCES INC | $1,730,000 | – | 100,000 | +100.0% | 0.31% | – |
| DB | New | DEUTSCHE BANK AGput | $1,593,000 | – | 150,000 | +100.0% | 0.28% | – |
| FTSV | New | FORTY SEVEN INC | $1,168,000 | – | 73,000 | +100.0% | 0.21% | – |
| ESPR | New | ESPERION THERAPEUTICS INC NEput | $980,000 | – | 25,000 | +100.0% | 0.17% | – |
| STAA | New | STAAR SURGICAL COput | $775,000 | – | 25,000 | +100.0% | 0.14% | – |
| CHRS | New | COHERUS BIOSCIENCES INCcall | $700,000 | – | 50,000 | +100.0% | 0.12% | – |
| PTE | New | POLARITYTE INCput | $589,000 | – | 25,000 | +100.0% | 0.10% | – |
| ZYNE | New | ZYNERBA PHARMACEUTICALS INCput | $487,000 | – | 50,000 | +100.0% | 0.09% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.